<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04863222</url>
  </required_header>
  <id_info>
    <org_study_id>2019-0994</org_study_id>
    <nct_id>NCT04863222</nct_id>
  </id_info>
  <brief_title>Clinical and Radiographic Success of MTA vs Biodentine</brief_title>
  <official_title>Clinical and Radiographic Success of Mineral Trioxide Aggregate (MTA) vs Septodont Biodentine in Primary Molars in Pulpotomy and Indirect Pulp Cap Treatments</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Geisinger Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Geisinger Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this prospective study is to compare the clinical and radiographic success of&#xD;
      MTA and Biodentine as a medicament in vital pulp therapy in maxillary and mandibular primary&#xD;
      molars in a pediatric population. There is limited research currently on Biodentine since&#xD;
      it's a novel product. Biodentine is less expensive than MTA and does not cause discoloration&#xD;
      like MTA. Biodentine may be an alternative medicament used for vital pulp therapy in primary&#xD;
      molars.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a interventional randomized split mouth prospective study that evaluates the clinical&#xD;
      and radiographic success of mineral trioxide aggregate (MTA) and Biodentine as pulpotomy and&#xD;
      indirect pulp cap (IPC) medicaments. Male and female participants ages two to twelve who need&#xD;
      at least two quadrants of treatment will be enrolled in the trial. Participants will be&#xD;
      treated at Geisinger Medical Center, Danville, and Geisinger Bloomsburg Hospital operating&#xD;
      rooms for full mouth rehabilitation. Each participant must have at least two matched&#xD;
      bilateral carious primary molars that require either pulpotomy or indirect pulp cap.&#xD;
      Maxillary and mandibular primary first and second molars who receive pulpotomy and /or&#xD;
      indirect pulp cap will be compared. The research will be split mouth design where the primary&#xD;
      molar on one side will get MTA as the pulpotomy or IPC medicament and the corresponding&#xD;
      primary on the other side will get Biodentine as the pulpotomy or IPC medicament in the same&#xD;
      arch.&#xD;
&#xD;
      The procedures will be performed according to standards of the American Academy of Pediatric&#xD;
      Dentistry (AAPD), by IRB approved investigators. Data will be extracted from the electronic&#xD;
      health record (EHR) and TigerView dental radiograph imaging software. Data will be recorded&#xD;
      using REDCap. Clinical and radiographic follow up of patients will be every 6 months since&#xD;
      date of procedure for 3 years. Follow up will be done at the Geisinger Pediatric Dental&#xD;
      Clinic at Danville or Milton.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 12, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of clinical success in pulpotomies and indirect pulp caps</measure>
    <time_frame>4 years</time_frame>
    <description>To compare the rate of clinical success in primary molars using MTA versus Biodentine in pulpotomies and indirect pulp caps. Subjects will been seen at follow-up standard of care visits every 6 months for 3 years to clinically evaluate if the treatment was successful, if any discoloration has occurred and assess for any signs or symptoms of an abscess.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of radiographic success in pulpotomies and indirect pulp caps</measure>
    <time_frame>4 years</time_frame>
    <description>To compare the rate of radiographic success in primary molars using MTA versus Biodentine in pulpotomies and indirect pulp caps. Subjects will been seen at follow-up standard of care visits every 6 months for 3 years where x-rays will be taken to determine if any abscess have formed.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">646</enrollment>
  <condition>Indirect Pulp Cap</condition>
  <condition>Pulpotomy</condition>
  <arm_group>
    <arm_group_label>MTA, then Biodentine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The participant will receive the standard of care procedure using MTA in on a right primary molar. A left primary molar will then be treated using Biodentine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Biodentine, then MTA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigators will prepare and treat a participants right primary molar with Biodentine. The participant will then receive the standard of care procedure using MTA in on a left primary molar.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Biodentine</intervention_name>
    <description>During a patients procedure, one tooth will receive Biodentine instead of MTA.</description>
    <arm_group_label>Biodentine, then MTA</arm_group_label>
    <arm_group_label>MTA, then Biodentine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>mineral trioxide aggregate (MTA)</intervention_name>
    <description>mineral trioxide aggregate (MTA)</description>
    <arm_group_label>Biodentine, then MTA</arm_group_label>
    <arm_group_label>MTA, then Biodentine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients ages of 2 to â‰¤12 years.&#xD;
&#xD;
          -  Bilateral symptomatic or asymptomatic vital primary molars with caries approximating&#xD;
             or into the pulp.&#xD;
&#xD;
          -  Patient who need a pulpotomy and/or indirect pulp cap treatments in two or more&#xD;
             quadrants.&#xD;
&#xD;
          -  Parents of patients who can provide consent in English.&#xD;
&#xD;
          -  Patients who need treatment in an operating room setting at Geisinger.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pre-operative radiographic or clinical symptoms associated with irreversible pulpitis&#xD;
             or necrotic pulp.&#xD;
&#xD;
          -  Radiographs not displaying furcation region of the tooth.&#xD;
&#xD;
          -  Patients with cardiac conditions who need prophylaxis for infective Endocarditis.&#xD;
&#xD;
          -  Patients with any type of cancer in the past or present.&#xD;
&#xD;
          -  Non-restorable molars.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gayatri Malik, DMD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Geisinger Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gayatri Malik, DMD</last_name>
    <phone>570-271-6355</phone>
    <email>gmalik1@geisinger.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Samantha R Crissinger</last_name>
    <phone>570-271-7499</phone>
    <email>srcrissinger@geisinger.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Geisinger</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gayatri Malik, DMD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 15, 2021</study_first_submitted>
  <study_first_submitted_qc>April 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2021</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

